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Much evidence indicates that individuals use tobacco primarily to experience the psy-
chopharmacological properties of nicotine and that a large proportion of smokers eventually
become dependent on nicotine. In humans, nicotine acutely produces positive reinforc-
ing effects, including mild euphoria, whereas a nicotine abstinence syndrome with both
somatic and affective components is observed after chronic nicotine exposure. Animal
models of nicotine self-administration and chronic exposure to nicotine have been critical
in unveiling the neurobiological substrates that mediate the acute reinforcing effects of
nicotine and emergence of a withdrawal syndrome during abstinence. However, important
aspects of the transition from nicotine abuse to nicotine dependence, such as the emer-
gence of increasedmotivation and compulsive nicotine intake following repeated exposure
to the drug, have only recently begun to be modeled in animals. Thus, the neurobiologi-
cal mechanisms that are involved in these important aspects of nicotine addiction remain
largely unknown. In this review, we describe the different animal models available to date
and discuss recent advances in animal models of nicotine exposure and nicotine depen-
dence.This review demonstrates that novel animal models of nicotine vapor exposure and
escalation of nicotine intake provide a unique opportunity to investigate the neurobiological
effects of second-hand nicotine exposure, electronic cigarette use, and the mechanisms
that underlie the transition from nicotine use to compulsive nicotine intake.
Keywords: addiction, tobacco, self-administration, vapor, dependence, escalation, abstinence, withdrawal
INTRODUCTION
Studies on the neurobiological substrates of tobacco addiction
largely depend on the availability of suitable animal models. In
this review, we first describe the features of tobacco smoking and
nicotine abuse and dependence in humans. We then discuss the
limits and advantages of the most used animal models of nicotine
use and dependence and novel animal models of escalated nicotine
intake and exposure to nicotine vapor. The last section discusses
how these different animal models can be used to investigate the
neurobiological mechanisms that mediate nicotine reinforcement
and dependence.
FEATURES OF TOBACCO SMOKING, NICOTINE ABUSE, AND
DEPENDENCE IN HUMANS
Tobacco use is the leading cause of preventable disease and pre-
mature death, leading to 440,000 deaths annually in the United
States alone (Fellows et al., 2002). According to a recent review
(Giovino et al., 2012), 24% of the United States population older
than 15 years of age are cigarette smokers, and 1.8% are smokeless
tobacco users. Cigarette smoking appears to be more central to
the epidemiology of nicotine addiction compared with smokeless
tobacco abuse. However, chewing tobacco, dry snuff, and moist
snuff are a concern in certain countries (Bhattacharyya, 2012;
Giovino et al., 2012). The rapid growth of electronic cigarette use
worldwide (Caponnetto et al., 2012) is also an important health
concern that requires the development of novel animal models of
exposure to nicotine vapor.
ACUTE EFFECTS OF SMOKING
The primary psychoactive ingredient responsible for tobacco use
is nicotine (Cummings and Mahoney, 2006), although tobacco
smoke also contains more than 4,000 additional chemicals, many
of which have psychoactive properties or may act in concert with
nicotine to contribute to smoking dependence (Clemens et al.,
2009; Hoffman and Evans, 2013). Cigarettes typically contain 10–
14 mg of nicotine (Kozlowski et al., 1998), of which 1–1.5 mg is
absorbed systemically in the lungs through inhalation (Armitage
et al., 1975; Benowitz and Jacob, 1984). Nicotine rapidly enters the
pulmonary venous circulation, reaches the brain within 10–20 s,
and readily diffuses into brain tissue where it binds to nicotine
acetylcholine receptors (nAChRs; Benowitz et al., 1988). The rate
of absorption of smokeless tobacco products, with the exception of
electronic cigarettes, is considerably slower (30 min to reach max-
imum blood levels), accounting for a lower abuse potential for
these products (Benowitz et al., 1988). Acutely, cigarette smoking
is reported to induce positive reinforcing effects, including mild
euphoria,heightened arousal, reduced appetite, and reduced stress,
anxiety, and pain (Pomerleau et al., 1984; Pomerleau and Pomer-
leau, 1992; Stolerman and Jarvis, 1995). However, the specific role
for nicotine in these reinforcing effects is still unclear because of the
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difficulties performing intravenous nicotine self-administration in
humans. However, smokers who self-administer nicotine report
an overall profile of rewarding sensations, including mild eupho-
ria, increased comfort, “drug liking,” and reduced negative mood
and pain sensation, accompanied by negative effects, such as ten-
sion and jitteriness (Henningfield and Goldberg, 1983; Perkins
et al., 1994; Harvey et al., 2004; Sofuoglu et al., 2008; Rose et al.,
2010). Thus, nicotine itself can serve as an effective reinforcer, at
least among experienced smokers. However, the mixed subjective
reports, early difficulties obtaining reliable intravenous nicotine
self-administration in animals, and direct comparisons in animal
models suggest that the reinforcing efficacy of nicotine is lower
than other drugs of abuse (Risner and Goldberg, 1983; Manzardo
et al., 2002; Le Foll and Goldberg, 2009). Non-nicotinic aspects of
tobacco smoke, such as its other constituents (e.g., acetaldehyde,
nornicotine, and harman) and sensory stimulation could substan-
tially contribute to its abuse and addictive potential (Belluzzi et al.,
2005; Rose, 2006; Rose et al., 2010; Kapelewski et al., 2011).
TOBACCO DEPENDENCE
Patterns of smoking among dependent smokers
Dependent smokers maintain relatively stable nicotine blood lev-
els during waking hours (Benowitz and Jacob, 1984), with plasma
levels ranging between 20 and 50 ng/ml. To maintain these rel-
atively constant nicotine levels, smokers efficiently regulate the
rate and intensity of cigarette smoking (Ashton and Watson,
1970; Benowitz, 1986). For example, smokers will compensate
for reduced nicotine content when smoking cigarettes with lower
nicotine yield than their usual brand (Russell et al., 1980; Maron
and Fortmann, 1987).
Nicotine withdrawal and the escalation of nicotine intake
Discontinuation of smoking, even for only several hours, leads to
withdrawal symptoms that peak within 1 week and may persist for
up to 6 months (Hughes et al., 1991; Hughes, 2007; Markou, 2008).
Nicotine withdrawal includes both somatic symptoms, such as
bradycardia, gastrointestinal disturbances, and, increased appetite,
and affective symptoms, such as nicotine craving, heightened anx-
iety, hyperalgesia, depressed mood, and irritability (Pomerleau
et al., 1984; Hughes et al., 1991; Zaniewska et al., 2009; Rose et al.,
2010). Converging evidence shows that avoidance of the affective
symptoms of nicotine withdrawal, rather than somatic symptoms,
plays a central role in the maintenance of nicotine dependence
(Koob et al., 1993). It has been hypothesized that during the tran-
sition to dependence, the motivation to take drugs is caused by
a shift from the positive reinforcing properties of the drug to
its ability to attenuate the negative effects of abstinence. Thus,
the negative affective states associated with abstinence potentiate
the incentive value of nicotine to promote the escalation of com-
pulsive drug intake through negative reinforcement mechanisms
(Solomon and Corbit, 1973; Koob and Le Moal, 2001; Koob, 2010).
Adolescence and the escalation of tobacco smoking
Tobacco smoking typically begins in adolescence, with 14% of 15-
year-olds and 22% of 17-year-olds reporting cigarette smoking
(Substance Abuse and Mental Health Services Administration,
2003). Prospective studies report that ∼30–50% of adolescents
and young adults who had initiated non-daily smoking showed
an escalation in daily smoking within 4–5 years (U.S. Department
of Health and Human Services, 1994, 2012; Tucker et al., 2003).
For example, one 4-year prospective study reports that 53% of
sixth-graders who experimented with smoking experience depen-
dence symptoms, and 40% experience escalation to daily smok-
ing (Doubeni et al., 2010). Some adolescents and young adults
who experiment with smoking will eventually quit or remain
light smokers (one to five cigarettes/day) or intermittent smokers
(“chippers”; Shiffman, 1989; Shiffman et al., 1994), a subpopula-
tion that encompasses up to 25–33% of all smokers (Coggins et al.,
2009).
Various psychosocial factors, such as peer smoking and par-
enting style, have been suggested to contribute to the escalated
smoking behavior of certain adolescents (Robinson et al., 2003;
Kim et al., 2009; Dal Cin et al., 2012). Interestingly, studies suggest
that, contrary to the common perception, symptoms of nicotine
dependence, most commonly craving for tobacco and withdrawal
symptoms (Gervais et al., 2007; Doubeni et al., 2010; Zhan et al.,
2012), can develop at very early stages of initial intermittent smok-
ing, even with as few as two cigarettes per week (DiFranza et al.,
2002). According to Zhan et al. (2012), 20% of adolescents who
smoke fewer than 100 cigarettes in their lifetime report experienc-
ing “smoking to relieve restlessness” and “irritability.”As expected,
the early appearance of such symptoms of nicotine dependence
predicts future escalation to daily chronic smoking (DiFranza
et al., 2002, 2007; Dierker and Mermelstein, 2010; Doubeni et al.,
2010). In contrast, people who engage in non-daily smoking with-
out escalation (“chippers”) have very few or no symptoms of
dependence, and their smoking experience is primarily associ-
ated with positive rather than negative reinforcement (Coggins
et al., 2009). Thus, intermittent tobacco use associated with with-
drawal symptoms can promote the escalation of smoking behavior,
which in turn accelerates the appearance of additional symptoms
of dependence (Doubeni et al., 2010).
The importance of nicotine withdrawal as a negative reinforcer
in the escalation of smoking is also suggested by the calming effects
of nicotine when given after even a short period of abstinence, a
primary reason given by both adults and adolescents for smok-
ing (Dozois et al., 1995; Parrott, 1995). Although nicotine has
anxiolytic properties under certain conditions (Pomerleau et al.,
1984; Perkins and Grobe, 1992; Juliano and Brandon, 2002), it has
also been argued that the calming effects of nicotine in depen-
dent smokers represent the reversal of the negative affect induced
by nicotine deprivation (Parrott, 1995, 1998, 2003). Thus, esca-
lation may be more common among individuals with difficulties
regulating negative affect, who are prone to develop withdrawal
symptoms, and who have high expectancy of the calming effects
of smoking (Heinz et al., 2010).
SECOND-HAND SMOKE
One generally overlooked factor that may contribute to the escala-
tion of tobacco abuse, particularly among adolescents, is second-
hand smoking. In the United States, it has been estimated that
up to 60% of children are exposed to second-hand smoke (U.S.
Department of Health and Human Services, 2006). Nicotine from
moderate second-hand smoke exposure results in an increase in
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plasma nicotine concentration of approximately 0.2 ng/ml and to
substantial brain α4β∗2 nAChR occupancy (19%) in both smok-
ers and non-smokers compared with 0.87 ng/ml and 50% α4β∗2
nAChR occupancy from actively smoking one cigarette (Brody
et al., 2006, 2011). Although second-hand smoking is clearly
linked to serious illnesses among non-smokers (U.S. Department
of Health and Human Services, 2006), including asthma, heart
disease, sudden infant death syndrome, and cancer, it is currently
unclear whether second-hand smoke can also contribute to the
initiation and escalation of smoking. It is well documented that
adolescents exposed to smoking by family members and peers
are more likely to initiate and escalate smoking behavior (Brook
et al., 2009; Leonardi-Bee et al., 2011; Wang et al., 2011). How-
ever, various psychological, psychosocial, and genetic factors may
mediate this effect (Ajzen and Fishbein, 1980; O’Byrne et al., 2002;
Audrain-McGovern et al., 2007). Nevertheless, escalated smoking
can be observed in adolescent smokers with cotinine plasma lev-
els comparable to levels of second-hand smoking in non-smokers
(DiFranza et al., 2007). Moreover, adults and children who are
non-smokers report symptoms of nicotine withdrawal after expo-
sure to high levels of second-hand smoke (Okoli et al., 2007;
Bélanger et al., 2008). Finally, prospective studies suggest that
high levels of nicotine intake from second-hand smoking during
childhood predict smoking behavior in teenage years, even when
accounting for various social and environmental factors (Becklake
et al., 2005). However, the controlled experimental conditions that
are required to test the causal role of second-hand smoking in the
escalation of smoking can only be employed in animal models and
will be discussed below.
ELECTRONIC CIGARETTES
Electronic cigarettes deliver nicotine through the battery-powered
vaporization of a nicotine/propylene-glycol solution. Electronic
cigarettes (e-cigarettes) are thus generally less harmful than regular
cigarettes because they deliver nicotine without the various toxic
constituents of tobacco smoke (Cahn and Siegel, 2011; Etter and
Bullen, 2011; O’Connor, 2012). According to a recent survey, 3.4%
of the total population, including 11.4% of current smokers, 2.0%
of former smokers, and 0.8% of never-smokers, use e-cigarettes
(Pearson et al., 2012). Most smokers claim to use e-cigarettes for
smoking cessation/reduction, and their use appears to enhance the
motivation to quit (Etter and Bullen, 2011; Wagener et al., 2012).
Indeed, two surveys reported that most smokers who used e-
cigarettes decreased or completely quit smoking within 6 months
(Polosa et al., 2011; Siegel et al., 2011). However, it is unclear
the degree to which such reports coincide with the efficacy of e-
cigarettes as nicotine delivery devices. Vansickel and Eissenberg
(2013) report that experienced users who were allowed to use
their own customized e-cigarettes reach blood nicotine concen-
trations similar to those obtained by regular cigarettes. However,
other studies report that nicotine delivery greatly varies between
brands but is generally lower than that of regular cigarettes, with
certain brands delivering nicotine doses that are too low to be
detected (Bullen et al., 2010; Vansickel et al., 2010; Goniewicz et al.,
2013). These studies report that e-cigarette use reduces craving
and partially alleviated withdrawal symptoms despite the low to
moderate blood nicotine levels. The effect of e-cigarette use on
the brain stress and reward systems and vulnerability to become
dependent or relapse is unknown and needs to be addressed using
novel animal models. Another key question that needs to be inves-
tigated is the possible role of e-cigarettes as a gateway product to
other drugs of abuse (Etter, 2012).
ANIMAL MODELS OF NICOTINE ABUSE AND DEPENDENCE
NON-CONTINGENT EXPOSURE TO NICOTINE
Most research on the behavioral and biological effects of nicotine
involved experimenter-administered nicotine, given by subcuta-
neous (s.c.) or intraperitoneal (i.p.) injections (see Figure 1).
Non-contingent nicotine injections were instrumental in identify-
ing the effects of acute and chronic exposure to nicotine on a wide
variety of phenomena, including locomotor activity (Clarke and
Kumar, 1983), anxiety-like behavior (Irvine et al., 1999; Cheeta
et al., 2001), feeding behavior (Clarke and Kumar, 1984), pain
(Sahley and Berntson, 1979), the development of tolerance to
such effects (Collins et al., 1988), and the brain systems involved
(Rosecrans and Meltzer, 1981; Clarke et al., 1988; Niijima et al.,
2001).
Conditioned place preference
In this model of drug reward, animals are tested for the develop-
ment of conditioned preferences for distinct drug-paired environ-
ments (Carr et al., 1989). Achieving nicotine-induced conditioned
place preference (CPP) in rodents has proven to be challenging
compared with other drugs of abuse, and findings have been
inconsistent. Nicotine-induced CPP is observed in some studies
(Fudala et al., 1985; Horan et al., 1997; Ashby et al., 2002; Le Foll
and Goldberg, 2005) but not in others (Clarke and Fibiger, 1987;
Acquas et al., 1989; Jorenby et al., 1990; Parker, 1992). Nicotine can
also induce conditioned place aversion (CPA; Horan et al., 1997;
Laviolette and van der Kooy, 2003). The ability to achieve nicotine-
induced CPP is facilitated by the use of a “biased” place preference
procedure (i.e., pairing the drug with the initially non-preferred
compartment of the CPP apparatus; Le Foll and Goldberg, 2005).
The reasons for the difficulty obtaining CPP are unclear and may
be related to the weak rewarding properties of nicotine and very
narrow dose-response curve.
Dependence induction
Termination of repeated nicotine injections in rodents results in
behavioral and physiological states consistent with drug with-
drawal (see review by Malin, 2001), such as heightened stress
responses (Benwell and Balfour, 1979), the disruption of appet-
itive operant responding (Ford and Balster, 1976; Carroll et al.,
1989), and weight gain (Grunberg et al., 1986; Levin et al.,
1987). The induction of nicotine dependence by subcutaneous
nicotine delivery via osmotic minipumps has gained popular-
ity since its first introduction by Malin et al. (1992). In this
method, dependence is induced by ≥6 days of continuous subcu-
taneous nicotine infusion (commonly ≥3.16 mg/kg free base/day
in rats and ≥12 mg/kg/day in mice). Withdrawal is subsequently
induced by terminating the infusion (peaking within 18–22 h;
Malin et al., 1992) or precipitated by injecting nAChR antag-
onists, such as mecamylamine (Malin et al., 1992; Isola et al.,
1999; Damaj, 2000; Malin, 2001). The symptoms of withdrawal
www.frontiersin.org June 2013 | Volume 4 | Article 41 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cohen and George Animal models of nicotine use and dependence
FIGURE 1 | Effects of acute/chronic non-contingent nicotine exposure,
limited/extended access to nicotine self-administration (NSA), and
withdrawal from chronic nicotine on measures of reward threshold
(ICSS), anxiety-like behavior, and reward (CPP) or aversion (CPA). Note
that the effect of withdrawal from chronic nicotine on the reward
thresholds differed depending on the type of nicotine delivery. 1.
Huston-Lyons and Kornetsky (1992), 2. Bozarth et al. (1998a), 3. Bozarth
et al. (1998b), 4. Bespalov et al. (1999), 5.Watkins et al. (2000a), 6.
Harrison et al. (2002), 7. Cryan et al. (2003), 8. Kenny and Markou (2005), 9.
Kenny and Markou (2006), 10. Kenny et al. (2009), 11. Johnson et al.
(2008), 12. Paterson et al. (2008), 13. Bruijnzeel et al. (2009), 14. Spiller
et al. (2009), 15. Yamada et al. (2010) 16. Harris et al. (2011); 17. Brioni et al.
(1993); 18. Irvine et al. (1999), 19. Irvine et al. (2001), 20. Tucci et al. (2003);
21. Biala and Budzynska (2006), 22. Stoker et al. (2008), 23. Cippitelli et al.
(2011), 24. Le Foll and Goldberg (2005), 25. Miyata et al. (2011), 26. Suzuki
et al. (1996), 27. Shram et al. (2008), 28. Grieder et al. (2012), 29. Grieder
et al. (2010), 30. Damaj et al. (1994), 31. Sahley and Berntson (1979), 32.
Craft and Milholland (1998), 33. Yang et al. (1992), 34. Galeote et al. (2006),
35. Lough et al. (2007), 36. Grabus et al. (2005), 37. Jackson et al. (2008),
38. Schmidt et al. (2001), 39. Yang et al. (1992).
are commonly divided into “somatic” signs that resemble opi-
ate withdrawal (e.g., teeth-chattering, chewing, writhing, tremors,
and body shakes; Malin et al., 1992). Although a well-accepted
marker for nicotine dependence, these somatic withdrawal signs
do not appear to be similar to those in humans or strongly pre-
dict drug use or relapse compared with affective symptoms (Koob
and Le Moal, 2001; Hughes, 2007). Affective symptoms can be
measured using CPA to nicotine withdrawal (Shram et al., 2008;
Jackson et al., 2009), anxiety-like behavior (Wilmouth and Spear,
2006), and increased reward thresholds in the intracranial self-
stimulation (ICSS) paradigm. The increased reward thresholds are
interpreted as reflecting a state of dysphoria or reduced ability to
experience reward (Watkins et al., 2000a; Vlachou et al., 2011).
Hyperalgesia, a withdrawal symptom that may be considered
partly somatic and partly affective, is also observed in rodents fol-
lowing spontaneous or mecamylamine-induced withdrawal from
chronic non-contingent nicotine delivery (Schmidt et al., 2001;
Damaj et al., 2003; Jackson et al., 2009, 2010). Hyperalgesia in
such studies is operationally defined as increased sensitivity to
nociceptive stimuli, usually in the form of tail-flick or hot-plate
tests of latency to respond to noxious thermal stimuli.
Non-contingent exposure to nicotine is a simple and efficient
way to induce nicotine dependence in animals and led to a great
deal of findings regarding the possible neurobiological mecha-
nisms of reward, dependence, and withdrawal (Malin, 2001; Malin
and Goyarzu, 2009). However, the validity of this approach is
limited when one wants to specifically investigate the neurobi-
ological mechanisms that underlie the transition from occasional
to compulsive use. Most importantly, contingent drug exposure
(i.e., cigarette smoking and nicotine self-administration) and non-
contingent exposure have very different psychological and physi-
ological effects and recruit different brain systems (Dworkin et al.,
1995; Markou et al., 1999). Nicotine absorption through subcuta-
neous or intraperitoneal administration is much slower than that
achieved through inhalation, and the speed of administration has
been shown to critically influence the reinforcing effects of drugs
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of abuse (Liu et al., 2005; Sorge and Clarke, 2009; but see Crom-
bag et al., 2008). While minipumps deliver nicotine 24 h per day
at a constant rate, humans smoke nicotine intermittently and not
during sleep. Finally, the daily amount of nicotine typically deliv-
ered by minipumps (3.16 mg/kg) is similar to an average adult
who smokes five packs of cigarettes, an amount consumed only by
exceptionally heavy smokers (Armitage et al., 1975; Benowitz and
Jacob, 1984). However, when differences between the metabolic
rate of rats (nicotine half life= 45 min; Adir et al., 1976; Plowchalk
et al., 1992) and humans (half life= 2 h) are taken into account,
the actual disparity between the amounts absorbed is minimized
(Malin, 2001), although comparisons remain difficult.
NICOTINE SELF-ADMINISTRATION
The self-administration method assesses an animal’s propensity
to self-administer a drug delivered (usually intravenously) con-
tingently upon the emission of an operant response, usually a
lever-press or nosepoke (Meisch and Lemaire, 1993). Since the
early 1980s, an increasing number of laboratories have reported
reliable rates of operant responding in nicotine self-administration
studies with rodents (Corrigall and Coen, 1989; Donny et al., 1995;
Watkins et al., 1999; Corrigall et al., 2000), but compared with
other drugs of abuse, stable rates of nicotine self-administration
remains difficult to establish and require careful control of a rela-
tively high number of experimental parameters, such as the drug
infusion duration, prior food training, restricted diets, and the
need for cued infusions of nicotine (Henningfield and Gold-
berg, 1983; Collins et al., 1990; Stolerman and Jarvis, 1995; Le
Foll and Goldberg, 2005; Chaudhri et al., 2006). At least some of
the described difficulties obtaining nicotine self-administration
may be related to the aversive properties of the drug (Benowitz,
1990). The difference between the rewarding and aversive doses
of nicotine appears to be relatively small. Specifically, rats will
intravenously self-administer nicotine at doses of 0.01–0.06 mg/kg
(e.g., Corrigall and Coen, 1989; Donny et al., 1995; Shoaib et al.,
1997), while an intravenous nicotine dose of 0.1 mg/kg has been
reported to cause seizures (Hanson et al., 1979; Corrigall and
Coen, 1989). Thus, when the behavioral criteria for demonstrating
nicotine’s reinforcing properties require that animals repeatedly
self-administer the drug, the likelihood of an accumulating blood
nicotine concentration that is no longer within the reinforcing
dose range is greatly elevated (see Rose and Corrigall, 1997).
ESCALATION OF NICOTINE SELF-ADMINISTRATION
Rats allowed 1–3 h/day access to nicotine self-administration
maintain stable and relatively low intake for weeks, exhibit very
limited, if any, spontaneous withdrawal symptoms, and do not
show increased motivation for nicotine after abstinence (Pater-
son and Markou, 2004; George et al., 2007; Cohen et al., 2012).
The model of limited access to drug self-administration is highly
relevant to the positive-reinforcement processes that account for
the initiation and maintenance of occasional/recreational drug
users but not for the transition to drug dependence, which is
characterized in humans by escalated drug intake (Koob et al.,
2004), robust somatic and affective withdrawal symptoms, and
most importantly increased motivation for nicotine after pro-
tracted abstinence (Perkins et al., 2009). In contrast, rats exposed to
extended (6–23 h) daily opiate, cocaine, or methamphetamine self-
administration sessions show escalation in drug intake (Ahmed
and Koob, 1998, 1999; Ahmed et al., 2000; Ben-Shahar et al., 2004;
Greenwell et al., 2009) that is characterized by an upward shift in
the dose-effect function that could not be simply explained as the
result of a change in the sensitivity to the drug (i.e., pharmacolog-
ical tolerance or sensitization; Koob and Le Moal, 1997; Ahmed
and Koob, 1998). It has been hypothesized that the escalation of
drug intake reflects an allostatic increase in the hedonic set point
as a result of downregulation of brain reward systems and recruit-
ment of brain stress systems (Ahmed and Koob, 1998; Koob and
Kreek, 2007). In line with this hypothesis, the escalation of opi-
ate and cocaine intake is correlated with a progressive elevation
in baseline reward thresholds (Ahmed et al., 2002; Kenny et al.,
2006). Further supporting the validity of the escalation model for
human addiction, the escalation of cocaine self-administration
has also been shown to be accompanied by increased suscepti-
bility to reinstatement (Mantsch et al., 2004; Wakabayashi et al.,
2010) and increased stress reactivity (Aujla et al., 2008). How-
ever, the escalation of nicotine intake is not observed when rats
are allowed daily extended access (6–24 h/day; 20–40 days) to
nicotine (Cox et al., 1984; Valentine et al., 1997; DeNoble and
Mele, 2006; Kenny and Markou, 2006; O’Dell et al., 2007), despite
exhibiting levels of nicotine intake similar to human smokers (rats:
0.2–1.5 mg/kg/day; humans: 0.14–1.14 mg/kg/day; Benowitz and
Jacob, 1984), and physical dependence as measured by sponta-
neous and mecamylamine-precipitated somatic signs (Paterson
and Markou, 2004; O’Dell et al., 2007). Moreover, in contrast to
the increased reward thresholds observed after extended access
to cocaine, heroin, and methamphetamine, repeated exposure to
nicotine self-administration (1–12 h/day for 20 days) has been
shown to induce a long-lasting decrease in reward thresholds
(Kenny and Markou, 2006), a result opposite to that observed after
chronic exposure to osmotic minipumps (Epping-Jordan et al.,
1998; Watkins et al., 2000a; see Figure 1). These results suggest
either that nicotine dependence differs from dependence on the
other drugs of abuse or that modeling the transition to escala-
tion of compulsive nicotine intake requires revision of the existing
model.
As discussed above, nicotine dependence commonly develops
as adolescents and young adults who smoke intermittently escalate
their drug intake. It has been repeatedly shown that intermit-
tent access to alcohol leads to higher levels of alcohol intake than
continuous access, suggesting that neurobiological changes that
underlie dependence may be more readily triggered by repeated
cycles of withdrawal followed by increased intake (Sinclair and
Senter, 1967; O’Dell et al., 2004; Lopez and Becker, 2005; Becker
and Baros, 2006). Thus, a model of dependence-induced exces-
sive nicotine intake was developed in our laboratory, in which rats
are allowed to self-administer nicotine 4 days per week for either
23 h/day (extended access) or 1 h/day (limited access), followed by
2–3 days of abstinence. Rats with extended access exhibit a pro-
nounced increase in nicotine intake in the first post-abstinence
session, with a gradual return to baseline intake levels within the
remaining three daily sessions (George et al., 2007; O’Dell and
Koob, 2007). This nicotine deprivation effect does not occur in rats
with limited access to nicotine, suggesting that the extended-access
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model has better validity for studying the increased motivation
for nicotine during abstinence. Moreover, 1–12 h/day of access to
nicotine self-administration results in either decrease or no change
in brain reward threshold during abstinence (Kenny and Markou,
2006; Patterson et al., 2008), while extending the access to 22 h/day
produces an increase in brain reward threshold during the first
3 days of abstinence (measured during extinction of nicotine self-
administration, Harris et al., 2011). This result is in accordance
with the increase in brain reward threshold observed during with-
drawal (Epping-Jordan et al., 1998) and conditioned withdrawal
(Kenny and Markou, 2005) after chronic exposure to nicotine
minipump, and with the increase dysphoria, depressed mood,
anxiety, and frustration reported in humans during abstinence
(Hughes et al., 1991).
Based on these results, we developed a novel animal model
of the escalation of nicotine intake, in which rats have extended
(21 h/day) but intermittent (every 24–48 h) access to nicotine
self-administration (0.03 mg/kg). Escalation occur only when the
rats are allowed extended but not limited access (Cohen et al.,
2012), and is associated with increased motivation to take nico-
tine on a progressive-ratio schedule of reinforcement and with a
more intense somatic signs following precipitated withdrawal. In
line with the hypothesis that tobacco smoking is more reinforc-
ing/addictive than pure nicotine because of non-nicotine com-
pounds, such as monoamine oxidase inhibitors (MAOIs; Berlin
and Anthenelli, 2001; Fowler et al., 2003; Guillem et al., 2005,
2006), the escalation is dramatically increased when rats are pre-
treated with the MAOI phenelzine (2 mg/kg, i.p.,) prior to each
extended-access self-administration session.
As stated above, limited access (1–12 h/day) to nicotine self-
administration does not produce escalation of nicotine intake,
however, a recent report showed that rats with limited access
to nicotine self-administration (2 h/day) escalate their nicotine
intake if they are given access to nicotine 8–12 h into withdrawal
from exposure to nicotine vapor (Gilpin et al., 2013). Consider-
ing that this exposure to nicotine vapor was sufficient to produce
robust withdrawal symptoms (Gilpin et al., 2013), it suggests that
emergence of a negative withdrawal syndrome is required for the
development of escalation of nicotine intake (George et al., 2007;
Gilpin et al., 2013), and suggest that exposure to nicotine vapor
either passively (second-hand smoking) or actively (electronic cig-
arette) may have profound consequences on the acquisition and
relapse of smoking behavior.
EFFECTS OF NICOTINE EXPOSURE ANDWITHDRAWAL IN
ADOLESCENCE
Converging lines of evidence suggest that adolescence is a vulnera-
ble period in the development of tobacco addiction (O’Dell, 2009).
Specifically, compared to adult, adolescent rats show increased sen-
sitivity to the rewarding effects of nicotine as measured with both
self-administration (Levin et al., 2003; Chen et al., 2007) and the
CPP procedures (Belluzzi et al., 2004; Shram et al., 2006; Torres
et al., 2008). On the other hand, adolescent rats demonstrate lower
aversive responses to high nicotine doses measured with CPA and
conditioned taste aversion (Shram et al., 2006; Torres et al., 2008).
Interestingly, adolescent rats may be more sensitive also to the con-
tribution of non-nicotinic tobacco smoke ingredients of tobacco
as acetaldehyde, a major component of tobacco smoke, appears to
more readily enhance nicotine self-administration in adolescent
but not adult rats (Belluzzi et al., 2005).
In addition to the increased rewarding effects and reduced
aversive effect of nicotine in adolescents, studies using models
of withdrawal from chronic passive nicotine delivery suggest that
adolescent rats have a more benign nicotine withdrawal syndrome,
as reflected by lower levels of somatic signs (O’Dell et al., 2004;
Shram et al., 2008), withdrawal thresholds (O’Dell et al., 2006),
CPA (O’Dell et al., 2007), and anxiety-like behavior in the elevated
plus maze (Wilmouth and Spear, 2006).
Importantly, the human data on adolescence as a critical period
in the establishment of smoking behavior in adulthood is sup-
ported by the finding that exposure to nicotine during adolescence
is associated with enhanced rewarding effects of nicotine. For
example, adult rats that initiated nicotine self-administration dur-
ing adolescence, show higher levels of nicotine intake than rats that
initiated nicotine self-administration during adulthood (Adriani
et al., 2003) and rats that received nicotine during adolescence
show in adulthood greater nicotine-induced place preference
(Adriani et al., 2006) and increased anxiety induced withdrawal
(Slawecki et al., 2003). However, the transition from nicotine use
to nicotine addiction (i.e., escalation) has not yet been examined
in adolescent rats.
EXPOSURE TO CIGARETTE SMOKE AND NICOTINE VAPOR
Animal models that utilize inhalation as the route of administering
cigarette smoke or nicotine have exceptional face validity because
they best simulate the unique pharmacokinetic characteristics (i.e.,
rate of absorption and brain delivery) that are associated with
smoking, which may have implications for its addictive properties
(Benowitz, 1990). Moreover, the stimulation of the respiratory
tract by tobacco smoke (e.g., by local nicotinic receptors; Ginzel
and Eldred, 1977) may play a role in nicotine dependence (Rose
and Corrigall, 1997). Another advantage of inhalation-based mod-
els is that they are non-invasive and much less labor-intensive than
those that involve osmotic minipumps. Although current inhala-
tion technology allows only for non-contingent passive exposure
and not for self-administration, it is particularly suitable for the
study of the detrimental effects of second hand smoke and their
contribution to addiction in particular.
Automated smoke machines that deliver cigarette smoke to ani-
mals in exposure chambers have been used extensively to study
the toxic effects of mainstream and sidestream (“second hand”)
tobacco smoke (Hecht, 2005; Farkas et al., 2006; Coggins, 2007).
Particularly, chronic exposure to sidestream smoke simulating
environmental tobacco smoke has been recently shown to induce
behavioral and neurobiological changes in laboratory animals. In
primates, prenatal and postnatal environmental smoke exposure
induces neuronal damage to the cortex and midbrain (Slotkin
et al., 2006) and impaired memory (Golub et al., 2007). In rats,
chronic exposure during postnatal days 8–23 leads to perturbed
mitochondrial processes in the cerebellum that is associated with
a heightened locomotor response in a novel environment (Fuller
et al., 2012). Similar chronic exposure during adulthood results
in biochemical changes in several brain regions (hippocampus,
cerebellum, frontal cortex) indicative of enhanced inflammatory
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processes and cell death (Fuller et al., 2010) as well as in learning
and memory impairments (Jaques et al., 2012).
Repeated exposure to mainstream cigarette smoke (modeling
exposure of active smokers) induces effects similar to those of
nicotine injections, including nAChR-dependent analgesia in rats,
with the development of tolerance following repeated exposures
(Anderson et al., 2004; Simons et al., 2005), sensitization to the
effects of nicotine on locomotion (Suemaru et al., 1992; Bruijnzeel
et al., 2009), and dependence as indicated by mecamylamine-
precipitated somatic withdrawal signs and elevated reward thresh-
olds (Small et al., 2010; Yamada et al., 2010). Small et al. (2010)
reports that despite induction of a dependent state, nicotine self-
administration is decreased 24 h after the termination of 28 con-
secutive tobacco smoke exposure sessions (4 h/day) and returns
to control levels 5 days later. However, these results need to be
interpreted with caution because the levels of nicotine and car-
bon monoxide to which the rats were exposed were very high in
most of these studies. For example, average plasma nicotine lev-
els in dependent smokers are 10–50 ng/ml (Russell et al., 1980;
Benowitz and Jacob, 1984; Henningfield and Keenan, 1993), and
average blood carboxyhemoglobin (COHgb) saturation, result-
ing from carbon monoxide exposure, is 4–10% (Benowitz et al.,
1982; Turner et al., 1986; Law et al., 1997). Plasma nicotine con-
centrations in the cigarette smoke exposure studies described
above ranged from 38.5 (Bruijnzeel et al., 2009) to 95.4–188 ng/ml
(Anderson et al., 2004; Small et al., 2010; Yamada et al., 2010).
Although COHgb levels were not reported, carbon monoxide
levels in the chambers [150–402 parts per million (PPM)] were
40–400% higher than the level needed to induce COHgb satu-
ration of 10.5% (Harris et al., 2010). These are especially high
compared with the values in non-smokers exposed to second-
hand smoke (5.9 ng/ml of serum nicotine; Pacifici et al., 1995)
and carbon monoxide levels of 5–20 PPM (Office of Technol-
ogy Assessment, 1986), leading to COHgb levels of 4.43% (Yee
et al., 2010). In addition to nicotine, tobacco smoke contains
at least 4,000 additional substances, many of which are toxic
or psychoactive, further complicating data interpretation. For
example, rats exposed to high levels of carbon monoxide and
other toxins may develop adverse effects that will hinder their
motivation to take nicotine. Alternatively, some components of
tobacco smoke may negate certain effects of nicotine. This could
explain the finding that although daily nicotine (0.125 mg/kg, s.c.)
reverses the elevated reward thresholds induced by withdrawal
from chronic nicotine, cigarette smoke exposure that induces the
same serum nicotine levels (25–55 ng/ml) did not (Harris et al.,
2010). Thus, although cigarette smoke exposure uniquely allows
the determination of the net effect of tobacco smoke, isolating
the specific effects of different components of tobacco smoke is
difficult.
The recently developed model of nicotine vapor (George et al.,
2010; Gilpin et al., 2013) addresses this shortcoming. The vapor-
ization of nicotine is achieved without the use of heat by constantly
bubbling nicotine with air and allowing for the reliable induc-
tion of air-nicotine concentrations that induce blood nicotine
levels comparable to those of different tobacco exposure levels
(heavy smokers, moderate smokers, and second-hand smoking).
Intermittent exposure to nicotine vapor (0.2 mg/m3 for 8 h/day
for 7 days) produces a concentration of nicotine in the blood of
22 ng/m, which is in the range of moderate smokers, and induces
significant somatic withdrawal signs precipitated by mecamy-
lamine (George et al., 2010). The concentration of nicotine in
vapor chamber air can be adjusted to produce blood nicotine lev-
els that are relevant to heavy, regular, or second-hand smoking and
e-cigarette use. Moreover, as stated above, rats exposed to nicotine
vapor (7.5 mg/m3 over a 12-h period) to the point of dependence
produce an escalation of nicotine self-administration relative to
both their own baseline (200% increase) and non-dependent
controls.
Thus, models based on the inhalation of tobacco smoke or
pure nicotine have the potential to reliably detect the biological
mechanisms that are unique to the consumption of tobacco via
smoking and determine the possible contribution of constituents
in second-hand smoke, particularly nicotine, in the transition
to nicotine dependence, reflected by the escalation of nicotine
intake. Future studies will need to address this issue using relatively
low levels of nicotine/smoke exposure and examine the effects of
exposure to a combination of nicotine and certain other selected
constituents of tobacco smoke (e.g., acetaldehyde and harman) on
different aspects of tobacco dependence. Finally, nicotine vapor is
the only model available to date that can be used to investigate the
neurobiological effects of nicotine delivery by e-cigarettes on the
vulnerability to develop nicotine dependence and relapse.
NEUROBIOLOGICAL MECHANISMS OF NICOTINE ADDICTION
The different animal models of nicotine abuse and dependence
have been widely used to unveil the neurobiological mechanisms
that mediate the acute and chronic effects of nicotine. Models
of the acute reinforcing effects of nicotine were established more
than two decades ago, and the biological processes involved are
well-characterized. In contrast, the neurobiological mechanisms
that mediate the increased motivation for nicotine associated with
drug dependence are poorly known.
ACUTE EFFECTS OF NICOTINE
Nicotine acetylcholine receptors
Nicotine acetylcholine receptors are distributed throughout the
central nervous system (Paterson and Nordberg, 2000), and
their activation increases the release of various neurotransmit-
ters (Wilkie et al., 1993; McGehee et al., 1995; Clarke and Reuben,
1996; Pontieri et al., 1996; Yang et al., 1996). The acute reinforcing
and rewarding effects of nicotine are mediated by the activation of
nAChRs, which are composed of five subunits that can either be
homomeric or heteromeric (Millar and Gotti, 2009). Twelve dif-
ferent neuronal nAChR subunits (α2–α10 and β2–β4) have been
identified (Dani and Bertrand, 2007). Inactivation of α7-, α4-,
α6-, and β2-containing nAChRs by pharmacological or genetic
manipulations decrease nicotine self-administration in rodents
(Picciotto et al., 1988; Dwoskin et al., 1999; Markou and Pater-
son, 2001). These subunits likely mediate the acute reinforcing
effects of nicotine. In contrast, α5 knockout mice show increased
nicotine self-administration at a high unit dose, suggesting the
involvement of this subunit in mediating the aversive effects of
high nicotine doses (Fowler et al., 2011).
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Mesocorticolimbic system: dopamine
The acute reinforcing effects of nicotine and other drugs of
abuse are in part mediated by activation of the mesocorticolimbic
dopamine system (Koob and Le Moal, 2008). The mesocorticolim-
bic dopamine system includes dopaminergic neurons that origi-
nate in the ventral tegmental area (VTA) and project to the nucleus
accumbens (NAc), hippocampus, amygdala, and prefrontal cor-
tex (PFC). Indeed, nicotine exposure increases dopamine release
in mesolimbic terminal fields (Di Chiara, 2000). Rats will self-
administer nicotine directly into the VTA (Ikemoto et al., 2006),
and intra-VTA infusion of a nicotine antagonist decreases nicotine
self-administration (Corrigall et al., 1994). In addition, disruption
of dopamine transmission either systemically or in the VTA atten-
uates nicotine self-administration (Corrigall and Coen, 1991) and
prevents the reduction of brain reward thresholds induced by nico-
tine (Huston-Lyons et al., 1993). In the place preference procedure,
dopamine antagonists block nicotine-induced CPP (Acquas et al.,
1989), but in a study by Laviolette and van der Kooy (2003), nico-
tine infusion into the VTA dose-dependently induced CPA at low
dose and CPP at high doses, and systemic infusion of a dopamine
antagonist potentiated the rewarding effects of mid-range nicotine
doses and switched the motivational effects of a low concentration
from aversive to rewarding. These results appear to be contradic-
tory to those obtained with the self-administration model (Ike-
moto et al., 2006) and may suggest different roles for dopamine
in mediating specific functions of reward and reinforcement that
may be dose-dependent.
Glutamate, GABA, and acetylcholine
Nicotine increases dopamine neurotransmission in the mesocor-
ticolimbic system by activating nAChRs, particularly α4β2, on
dopaminergic neurons in the VTA (Nisell et al., 1994; Mansvelder
and McGehee, 2003) and nAChRs, particularly α7-containing glu-
tamatergic neurons that originate in the VTA, NAc, amygdala,
hippocampus, and PFC (Fu et al., 2000; Mansvelder and McGe-
hee, 2003) and project to dopaminergic neurons in the VTA
(Grillner and Svensson, 2000). Consequently, antagonists of vari-
ous glutamate receptors, including NMDA, AMPA, and mGluR5,
decrease nicotine self-administration, whether delivered system-
ically or into the VTA (Kenny et al., 2003, 2009; Patterson et al.,
2003; Liechti and Markou, 2008), and NMDA and AMPA receptor
antagonists block nicotine-induced dopamine release in the NAc
(Kosowski et al., 2004). Moreover, lesions of glutamatergic inputs
from the pedunculopontine tegmental nucleus (PPT) to VTA
inhibit nicotine self-administration and CPP (Lança et al., 2000;
Laviolette et al., 2002; Picciotto and Corrigall, 2002). The PPT also
contains cholinergic neurons that are activated by nicotine and
project to dopaminergic neurons in the VTA. Indeed, delivery of
an antagonist of non-α7 nAChRs to the PPT or lesions of cholin-
ergic neurons in the PPT reduced nicotine self-administration
(Lança et al., 2000; Corrigall et al., 2001, 2002; Alderson et al.,
2006). Finally, intra-VTA GABAergic neurons are activated by
nicotine and inhibit dopamine neurons. However nAChR on
GABAergic neurons desensitize faster than nAChRs on dopamine
neurons, leading to a facilitation of dopamine neuron firing
(Laviolette and van der Kooy, 2004). Accordingly, enhanced acti-
vation of GABAB receptors inhibits nicotine self-administration
and CPP in rats (Patterson et al., 2004, 2008; Le Foll et al.,
2008).
Endogenous opioids
The endogenous opioid system may also play an important role
in the rewarding and reinforcing effects of nicotine (for review,
see Berrendero et al., 2010). Briefly, endogenous opioid systems
include three main receptors, µ (MOR), δ (DOR), and κ (KOR;
Kieffer and Evans, 2009). Of the opioid peptides in the brain,
β-endorphin binds with a higher affinity to MORs than DORs
or KORs, and it is a main endogenous ligand for MORs. Dynor-
phins are the main endogenous ligands for KORs (Roth-Deri et al.,
2008). Nicotine enhances the release of endogenous opioid pep-
tides and modifies the expression of their receptors. For example,
acute nicotine induces increases in met-enkephalin, dynorphin,
and prodynorphin mRNA in the striatum of mice after acute
nicotine injection (Dhatt et al., 1995; Isola et al., 2009). Nicotine-
induced dopamine increase in the NAc can be blocked by the
administration of MOR antagonists or KOR agonists (Maison-
neuve and Glick, 1999). However, although systemic inhibition
of β-endorphin-MORs by pharmacological or genetic manip-
ulations generally reduces the rewarding effects of nicotine in
animal models (Berrendero et al., 2002; Göktalay et al., 2006;
Trigo et al., 2009), the blockade of opioid receptors in the VTA
and NAc does not interfere with nicotine self-administration in
rats (Corrigall and Coen, 1991; Corrigall et al., 2000). Interest-
ingly, prodynorphin knockout mice show enhanced acquisition of
nicotine self-administration (Galeote et al., 2009), suggesting that
the prodynorphin-KOR system may mediate the aversive effects
of nicotine, particularly at high doses, as was demonstrated with
other drugs of abuse (Mendizábal et al., 2006; Shippenberg et al.,
2007).
Serotonergic system
Serotonin [5-hydroxytryptamine (5-HT)] neurons in the median
and dorsal raphe nuclei provide the majority of 5-HT innervation
to the forebrain and are associated with appetitive behavior and
affect regulation (Steinbusch, 1984). Their involvement in nico-
tine reinforcement is suggested by nicotine-induced increases in
dorsal raphe neuron firing and 5-HT release (Ribeiro et al., 1993;
Li et al., 1998; Mihailescu et al., 1998, 2002; Martinez-Gonzalez
et al., 2002). Agonists of 5-HT2C receptors reduce nicotine self-
administration (Grottick et al., 2001) but not nicotine-induced
CPP (Hayes et al., 2009).
Endocannabinoids
Endocannabinoid systems may also be involved in the reward-
ing and reinforcing effects of nicotine. CB1 receptor antagonists
decrease nicotine self-administration and CPP in rodents (Cohen
et al., 2002; Le Foll and Goldberg, 2004; Merritt et al., 2008) and
the nicotine-induced enhancement of dopamine levels in the NAc
(Cohen et al., 2002).
CHRONIC NICOTINE ANDWITHDRAWAL
The pathological motivational state that characterizes dependence
on nicotine involves the appearance of negative affective states
when nicotine exposure is discontinued (i.e., nicotine withdrawal).
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These may involve disruptions of the same neurobiological mech-
anisms that are involved in the positive reinforcing effects of the
drug (i.e., within-system neuroadaptations) and recruitment of
stress systems (e.g., between-system neuroadaptations). This neg-
ative affective state may represent a negative reinforcer that will
enhance the incentive value of nicotine, leading to increased nico-
tine intake in an attempt to alleviate the negative emotional state
(Solomon and Corbit, 1973; Koob and Le Moal, 2001, 2008; Koob,
2008, 2010).
Spontaneous or precipitated withdrawal from chronic nico-
tine produces anxiety-like behavior, CPA, and elevations of brain
reward thresholds (Balerio et al., 2004; Jackson et al., 2008; John-
son et al., 2008). These affective and reward deficits likely involve
downregulation of dopaminergic neurotransmission in the meso-
corticolimbic system. Withdrawal from chronic nicotine results in
decreased tonic firing of dopamine neurons in the VTA (Grieder
et al., 2012) and decreases dopamine levels in the NAc (Fung et al.,
1996; Hildebrand et al., 1998). Chronic exposure to nicotine pro-
duces a desensitization of nAChRs (Dani and Heinemann, 1996;
Fenster et al., 1999; Picciotto et al., 2008) and an upregulation of
nAChRs (Marks et al., 1983, 1992; Changeux et al., 1984; Dani and
Heinemann, 1996; Koob and Le Moal, 2005). However, differences
exist between nAChRs. For example, brain nicotine concentra-
tions in an average smoker reach levels sufficient to desensitize
α4β2 nAChRs without affecting α7 nAChRs, which requires much
higher concentrations (Wooltorton et al., 2003). Glutamate release
is regulated by α7 nAChRs located presynaptically (Marchi et al.,
2002). Thus, during nicotine exposure, desensitization of α4β2
nAChRs on GABAergic neurons will suppress GABA release and
inhibit dopamine neurons in the VTA, whereas α7 nAChRs on
glutamatergic afferents will remain active and increase gluta-
mate release on dopamine neurons in this region, facilitating
dopamine secretion in the NAc (Dani, 2001; Wooltorton et al.,
2003). However, nicotine withdrawal produces an opposite effect,
with decreases in VTA glutamate levels and increases in VTA
GABA levels (Natividad et al., 2012). Consequently, antagonism
of presynaptic mGluR2/3 antagonists, known to negatively mod-
ulate glutamate release (Schoepp et al., 2003), attenuates reward
deficits associated with nicotine withdrawal in rodents and allevi-
ates the depressive-like symptoms related to nicotine abstinence in
humans (Kenny et al., 2003; Liechti and Markou, 2008). Inhibition
of glutamate transmission by the delivery of mGluR5 antago-
nists in rats and knocking out mGluR5 in mice further elevates
reward thresholds during nicotine withdrawal (Harrison et al.,
2002; Liechti and Markou, 2007; Stoker et al., 2012).
Endogenous opioids may play an important role in the devel-
opment of nicotine dependence, reflected by the resemblance
between the somatic signs induced by the cessation of nicotine
exposure and those of opiate withdrawal (Malin et al., 1993;
Watkins et al., 2000a) and the ability of the opioid receptor nalox-
one to induce somatic signs of withdrawal in heavy smokers
(Sutherland et al., 1995; Krishnan-Sarin et al., 1999). Nalox-
one administration in rodents chronically treated with nicotine
induces somatic signs of withdrawal (Malin et al., 1993; Balerio
et al., 2004; Biala et al., 2005),CPA,and elevations in reward thresh-
olds (Watkins et al., 2000a,b). MOR (Berrendero et al., 2002) and
proenkephalin (Berrendero et al., 2005) knockout mice chronically
exposed to nicotine show reduced somatic signs of withdrawal.
Interestingly, knockout of the prodynorphin gene does not impact
the somatic signs of nicotine withdrawal (Galeote et al., 2009).
Moreover, nicotine withdrawal is associated with increased pro-
dynorphin expression in the NAc (Isola et al., 2008). Thus, it can
be hypothesized that during chronic nicotine exposure, there is a
release of opioid peptides,which leads to downregulation of MORs
and upregulation of prodynorphin-KOR systems. These opposing
effects may combine to participate in the mediation of the somatic
and affective aspects of nicotine withdrawal.
There is also evidence that 5-HT neurotransmission is involved
in the mediation of nicotine dependence. Chronic nicotine treat-
ment decreases the concentration of 5-HT in the hippocampus and
increases the number of hippocampal 5-HT1A receptors (Benwell
and Balfour, 1979). This receptor upregulation may reflect reduced
levels of 5-HT input from the median raphe nucleus, which is
the main source of brain 5-HT and projects to various brain
areas, including the hippocampus and amygdala (Benwell et al.,
1990). During nicotine abstinence, decreased 5-HT, combined
with upregulated 5HT1 receptors, may contribute to symptoms
of depression and anxiety that are associated with 5-HT deficits
(Coppen, 1967; Young et al., 1985; Markou et al., 1998) and nico-
tine withdrawal (Hughes et al., 1991). Indeed, antagonism of 5-HT
receptors attenuates withdrawal-induced CPA in animals (Suzuki
et al., 1997) and anxiety in withdrawn human smokers (West et al.,
1991; Hilleman et al., 1992, 1994). Interestingly, a recent study
suggests that acute nicotine activates 5-HT neurons in the dorsal
raphe that are regionally distinct from those involved in nicotine
withdrawal (Sperling and Commons, 2011).
STRESS IN NICOTINE DEPENDENCE
Convergent lines of evidence (Koob and Le Moal, 2001, 2005)
suggest that stress [e.g., corticotropin-releasing factor (CRF) and
orexin] and anti-stress [e.g., neuropeptide Y (NPY)] systems are
involved in the emotional and motivational aspects of drug depen-
dence (see Bruijnzeel, 2012, for an extensive review) and are largely
localized to the extended amygdala, a forebrain macrostructure
composed of the bed nucleus of he stria terminalis (BNST), cen-
tral nucleus of the amygdala (CeA), and NAc shell (Heimer and
Alheid, 1991; Smith and Aston-Jones, 2008).
Corticotropin-releasing factor
Nicotine self-administration increases the release of adrenocorti-
cotropic hormone (ACTH) and cortisol/corticosterone (CORT;
Donny et al., 2000; Chen et al., 2008). Evidence suggests that
while CORT facilitates the reinforcing effects of drugs in non-
dependent subjects, high circulating levels of CORT, as a result
of repeated drug use, can feed back to shut off the hypothalamic-
pituitary adrenal (HPA) axis and sensitize extrahypothalamic CRF
systems, contributing to escalated and compulsive drug intake
(Vendruscolo et al., 2012). CRF is a neuropeptide that has three
paralogs – Ucn 1, 2, and 3 – and is involved in regulating the neu-
roendocrine autonomic and behavioral responses to stress (Vale
et al., 1981, 1983; Dunn and Berridge, 1990; Koob, 1999). Two
G-protein-coupled CRF receptors have been identified: CRF1 and
CRF2. Notably, although CRF and Ucn 1 have high selectively
for the CRF1 receptor, Ucn 2 and Ucn 3 have high selectivity for
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the CRF2 receptor (Bale and Vale, 2004). While activation of the
CRF1 receptor leads to increases in anxiety-like behavior, acti-
vation of the CRF2 receptor generally triggers a compensatory
anti-stress response. For example, selective CRF1 antagonists have
been shown to reduce anxiety-like behavior in animals (Griebel
et al., 1998; Deak et al., 1999; Zorrilla et al., 2002), whereas
the CRF2 receptor agonist Ucn 3 decreases behavioral stress
responses (Valdez et al., 2002, 2003). Various findings suggest that
recruitment of CRF–CRF1 systems, particularly in regions of the
extended amygdala, may be involved in producing the negative
emotional states during withdrawal or protracted abstinence from
chronic nicotine. First, precipitated nicotine withdrawal increases
Fos expression (i.e., neuronal activation) in the CeA. Second, CRF
levels in the basal forebrain (Matta et al., 2007) and CeA (George
et al., 2007) are elevated during nicotine withdrawal. Third, the
elevation of reward thresholds induced by nicotine withdrawal is
attenuated by intracerebroventricular or intra-CeA infusion of the
CRF1 antagonist d-Phe CRF12–41 and non-specific CRF antago-
nist α-helical CRF9–41 (Bruijnzeel et al., 2009; Marcinkiewcz et al.,
2009; Bruijnzeel, 2012) but not a CRF2 antagonist (Bruijnzeel et al.,
2009). Infusion of d-Phe CRF12–41 into the NAc shell, another
region of the extended amygdala, also blocks the withdrawal-
induced elevation in reward thresholds (Marcinkiewcz et al.,
2009). Fourth, a CRF1 antagonist (MPZP) administered systemi-
cally attenuates the abstinence-induced increases in nicotine intake
and nicotine withdrawal-induced anxiety-like behavior (George
et al., 2007). Finally, CRF1 antagonists administered systemically
attenuate the escalated intake of heroin and cocaine in rats with
extended access to the drug (Specio et al., 2008; Greenwell et al.,
2009).
Neuropeptide Y
Neuropeptide Y is a 36-amino-acid polypeptide with powerful
anxiolytic-like properties in various animal models of anxiety and
stress (Heilig and Murison, 1987; Broqua et al., 1995; Sajdyk et al.,
1999; Tovote et al., 2004). The involvement of NPY in addic-
tion was mainly studied with regard to alcohol dependence, with
alcohol-preferring rats having lower basal levels of NPY in the
CeA that correlate with greater levels of anxiety-like behavior com-
pared with alcohol non-preferring rats (Suzuki et al., 2004; Pandey
et al., 2005). Moreover, viral vector-induced overexpression of
NPY in the CeA decreases alcohol intake in alcohol-dependent
rats (Thorsell et al., 2007). These results suggest that downregula-
tion of the NPY system in the CeA may mediate the transition from
non-dependent to dependent alcohol intake. The role of NPY in
nicotine dependence has been less studied. Rylkova et al. (2008)
report that NPY prevents the somatic signs of withdrawal but not
elevation in brain reward thresholds that result from precipitated
nicotine withdrawal in rats. Yet, abstinence from nicotine induced
anxiety-like behavior that was associated with a decreased ratio of
NPY to CRF in the amygdala, suggesting an allostatic change in
both stress and anti-stress neuropeptide systems (Slawecki et al.,
2005; Aydin et al., 2011).
Norepinephrine
Several lines of evidence suggest that norepinephrine (NE) signal-
ing from the nucleus tractus solitarius (NTS) to extended amygdala
mediates the aversive effects of opiate and cocaine withdrawal (e.g.,
anxiety-like behavior; Smith and Aston-Jones, 2008). Moreover,
morphine withdrawal enhances subsequent morphine-induced
CPP, which is reduced by delivery of the α2-adrenoceptor ago-
nist clonidine (Nader and van der Kooy, 1996). The role of NE in
nicotine dependence has been less explored, but clonidine appears
to decrease anxiety and irritation associated with smoking ces-
sation and promote abstinence (Prochazka et al., 1992; Gourlay
et al., 2004). The few animal studies conducted have yielded con-
flicting results. Deficits in brain reward function during nicotine
withdrawal were attenuated by antagonism of α1-adrenoceptors
(Bruijnzeel et al., 2010) and antagonism of α2-adrenoceptors in
another study (Semenova and Markou, 2010). This is puzzling
given the positive effect of clonidine, a α2 agonist, in human absti-
nent smokers. More studies are needed to clarify the role of NE in
nicotine dependence.
Orexin/hypocretin
Orexin A (hypocretin-1) and orexin B (hypocretin-2) are neu-
ropeptides that have two known receptors, Hcrt-r1 and Hcrt-r2,
and regulate several processes, including arousal (Sutcliffe and de
Lecea, 2002; Taheri et al., 2002) and stress responses (Baldo et al.,
2003; Winsky-Sommerer et al., 2004). Orexin/hypocretin neurons
are especially abundant in the lateral hypothalamus and project to
various brain regions, including the extended amygdala (Peyron
et al., 1998; Baldo et al., 2003). Interestingly, intracerebroventric-
ular infusion of orexin A induces Fos activation in approximately
half of the CRF-containing neurons in the CeA (Sakamoto et al.,
2004). Orexin neurons also receive inputs from the amygdala
(Sakurai et al., 2005), and a possible positive feedback circuit
between hypothalamic orexin neurons and amygdala CRF neurons
has been suggested (Corrigall, 2009). Indeed, dependent smokers
during early withdrawal show a significant negative correlation
between hypocretin plasma concentration and nicotine craving
(von der Goltz et al., 2010). A recent study reports that nicotine
withdrawal increases hypocretin cell activity in the hypothalamus
and that the hypocretin-1 receptor antagonist SB334867 as well
as preprohypocretin knockout attenuate somatic nicotine with-
drawal signs in mice (Plaza-Zabala et al., 2012). This study also
revealed that the hypothalamic paraventricular nucleus (PVN) is
strongly involved in this effect. Infusion of SB334867 into this
region attenuates the somatic signs of withdrawal.
Nociceptin/orphanin FQ
Nociceptin/orphanin FQ is a 17-amino-acid peptide that shows
structural homology with the dynorphin A peptide (Reinscheid
et al., 1995) and binds to the nociceptin/orphanin peptide (NOP)
receptor. Nociceptin/orphanin FQ and NOP receptors are dis-
tributed throughout the central nervous system, with relatively
high densities in the extended amygdala, PFC, and VTA (Neal
et al., 1999). Nociceptin/orphanin FQ generally inhibits stress
responses by functionally antagonizing CRF activity (Ciccocioppo
et al., 2003). Chronic exposure to alcohol decreases the levels
of brain nociceptin/orphanin FQ (Lindholm et al., 2002), and
activation of the nociceptin/orphanin FQ system attenuates alco-
hol withdrawal symptoms and reverses increased anxiety-like
behavior associated with ethanol dependence (Economidou et al.,
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2011; Aujla et al., 2013). Nociceptin/orphanin FQ might be sim-
ilarly involved in nicotine dependence. NOP receptor knockout
mice, unlike wildtype mice, show a significant mecamylamine-
induced CPA to nicotine withdrawal (Sakoori and Murphy,
2009).
ESCALATION OF NICOTINE INTAKE
Unlike cocaine and opiates, daily extended self-administration
sessions do not induce escalation of nicotine intake but rather
a reduction in intake following the first daily session and sta-
ble intake afterward (Valentine et al., 1997; Kenny and Markou,
2006; O’Dell et al., 2007; Cohen et al., 2012). However, humans
typically do not have continuous access to smoking but instead
alternate between periods of access (daytime) and no access
(nighttime). The escalation of nicotine intake only occurs when
24–48 h of abstinence are given between extended-access (21 h)
sessions (Cohen et al., 2012). It is possible that escalation does
not take place when given continuous access because of nAChR
desensitization (see above), which requires a period ranging from
a few hours to a few days to recover (Collins et al., 1990, 1994;
Girod and Role, 2001). Additionally, the escalated intake of nico-
tine could reflect the increased incentive value of nicotine that
results from experiencing a negative affective state because of
recruitment of stress systems and downregulation of anti-stress
systems (Koob and Le Moal, 2001; Koob, 2010). Supporting such
a hypothesis, CRF levels in the CeA are increased during precipi-
tated withdrawal. Moreover, blocking CRF1 receptors systemically
with MPZP attenuates both the increase in anxiety-like behav-
ior during precipitated withdrawal and increase in nicotine intake
following 72 h of abstinence (George et al., 2007). In accordance
with the hypothesis that emergence of a negative emotional state
is required in order to observe escalation of nicotine intake is the
fact that rats with limited access to nicotine self-administration
(2 h/day) escalate their nicotine intake only if they are tested under
withdrawal from daily exposure to nicotine vapor that is suf-
ficient to produce a robust withdrawal syndrome (Gilpin et al.,
2013).
To further support the hypothesis that negative affective symp-
toms drive the escalation of nicotine self-administration, pos-
sible associations between anxiety-like behavior (among other
negative affective symptoms) and the escalation of nicotine
self-administration will need to be explored, and the possibil-
ity that manipulation of CRF and other stress and anti-stress
systems can block the escalation of nicotine intake should be
examined.
SUMMARY AND CONCLUSION
Animal models of the acute effects of nicotine have provided us
with ample evidence regarding the reinforcing and affective effects
of nicotine and neurobiological processes that mediate them.
These studies support a central role for the mesocorticolimbic
dopamine system and neuronal circuits that interact with it in the
acute reinforcing effects of nicotine. Studies using chronic pas-
sive delivery of nicotine via intracranial or intraperitoneal routes
of administration have provided evidence that chronic nicotine
dysregulates nAChRs and downregulates the same neurobiologi-
cal mechanisms that are involved in the positive reinforcing effects
of the drug. However, most of these studies did not examine the
relationships between these neurobiological alterations and moti-
vation to consume nicotine after dependence developed. Human
smokers tend to begin smoking intermittently, especially at early
ages, and quickly develop initial aversive symptoms of abstinence.
Their smoking behavior escalates until daily smoking reaches a sta-
ble high level that is considered compulsive. Novel models of esca-
lated nicotine intake will allow investigation of the mechanisms
that underlie the development of compulsive nicotine intake in
rats. Initial evidence suggests that recruitment of brain stress sys-
tems is a key factor in this process, but further research is needed.
Novel models of nicotine exposure that utilize inhalation also pro-
vide a unique opportunity to evaluate the effects of e-cigarette
use and second-hand smoking exposure on the vulnerability to
dependence and relapse.
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